S-777,469 is a drug developed by
Shionogi which is a
cannabinoid receptor agonist, with 128x selectivity for the
CB2 subtype, having a CB2 affinity of 36nM, and a
CB1 affinity over 4600nM.
^Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, et al. (April 2012). "Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent". Bioorganic & Medicinal Chemistry Letters. 22 (8): 2803–6.
doi:
10.1016/j.bmcl.2012.02.072.
PMID22444677.
^Haruna T, Soga M, Morioka Y, Hikita I, Imura K, Furue Y, et al. (2015). "S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission". Pharmacology. 95 (1–2): 95–103.
doi:
10.1159/000371890.
PMID25721168.
S2CID41617054.
^Haruna T, Soga M, Morioka Y, Imura K, Furue Y, Yamamoto M, et al. (2017). "The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice". Pharmacology. 99 (5–6): 259–267.
doi:
10.1159/000455916.
PMID28214870.
S2CID31692497.